DES-7114 / Eli Lilly, D. E. Shaw Research - LARVOL DELTA

Safety Evaluation of Glutaric Acid as a Novel Pharmaceutical Salt for First-In-Human Dosing. (PubMed, Toxicol Sci) - "The nonclinical safety of glutaric acid as a pharmaceutical counterion was assessed using LY3972406 hemi-glutarate hemi-hydrate (HG) as a model, with direct comparison to the LY3972406-hydrochloride (HCl) salt...Glutaric acid is a promising pharmaceutical counterion that lacks regulatory safety data. This first comprehensive Good Laboratory Practice-compliant nonclinical safety evaluation supports the viability of glutaric acid as an alternative pharmaceutical counterion to hydrochloride salts in drug development."

First-in-human • Journal • P1 data